-+ 0.00%
-+ 0.00%
-+ 0.00%

Kailera to Present Phase 3 Ribupatide Trial Designs at ObesityWeek 2026

PUBT·11/10/2026 12:11:18
Listen to the news
Kailera to Present Phase 3 Ribupatide Trial Designs at ObesityWeek 2026
  • Kailera Therapeutics will present Phase 3 ribupatide injection trial designs at ObesityWeek 2026, held November 14-17 in Washington, D.C.
  • November 15 presentations cover KaiNETIC-1, KaiNETIC-2 and KaiNETIC-3, evaluating ribupatide in people with obesity.
  • Research scheduled for November 16 examines real-world obesity medication management and unmet clinical needs among adults with severe obesity.
  • Hengrui Pharma will present Phase 3 HARBOR-1 findings for oral safiglipron on November 15; Kailera holds development rights outside Greater China.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100700PRIMZONEFULLFEED9874012) on November 10, 2026, and is solely responsible for the information contained therein.